Re: Now recruiting: ZEN-3694 and Talazoparib in Patients With Triple Negative Breast Cancer (TNBC)

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

tada

Rank: President [?]

Points: 7750 [?]

Votes: 40 Score: 3.4 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Now recruiting: ZEN-3694 and Talazoparib in Patients With Triple Negative Breast Cancer (TNBC)

in response to

Now recruiting: ZEN-3694 and Talazoparib in Patients With Triple Negative Breast Cancer (TNBC)

BearDownAZ

posted on May 06, 2019 06:09PM

Well if they have very encouraging results in the 3694/enzalutamide trial they may find the Bio International Conference June 3 - 6 to be an ideal place to make some sort of an announcement regarding a deal to sell 3694 or Zenith Epigenetics Ltd.